- AI-screener
- Securities US
- Eli Lilly and Company
Eli Lilly and Company
$769.88
$4.20
0.55%
6 Jun 20:00
$677.09
$972.53
52 weeks low/high
Market sentiment
Section about market participants' moods: bulls holding long positions (“longs”) and bears holding short positions (“shorts”).
Overall assessment
bullish sentiment increases
6day with a yield of4.37%
Long
100.00%Short
0.00%| Index | Bulls | Bears |
|---|---|---|
Confidence | — | |
Support | — | |
Cash flows | — |
Momentum
Indicators for analyzing trends in the instrument. Based on them you can choose the optimal moment to open or close a position.
Return/MDD
1.23Sentiment
BullishStart Date
06.02.2025Duration
4Yield
3.05%Avg.Yield
1.97%
Volatility
3.53%Max MDD
2.47%Avg. MDD
-4.15%Min Price
RUB 747.12Max Price
RUB 769.88
Protective stop levels
S/L 5%RUB 731.39 | S/L 10%RUB 692.89 | S/L 15%RUB 654.40 | |
|---|---|---|---|
Day | 14.61% | 0.28% | 0.00% |
Week | 51.57% | 18.18% | 3.94% |
Month | 75.11% | 51.47% | 31.49% |
Technical analysis
- Trend ClassFlat and Down
- Trend PowerAlmost flat
- PatternBroadering formation
- EMA-20Bearish reversal2025-05-01 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
- EMA-50Bearish reversal2025-05-05 the price crossed down the moving average line and getting closer to the MA, which means that the downside trend weakens.
- EMA-100Bearish reversal2025-05-01 the price crossed down the moving average line and demonstrates a downside trend.
- StochasticBullishThe stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: signal line crossed the middle level.
- RSIBearish recoveryRSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: entrance to the overbought zone.
- MACDBullish reversalOscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.
- Candle pattern typeBullish HaramiConsists of an unusually large black body followed by a small white body contained within large black body. It is considered as a bullish pattern when preceded by a downtrend.Date of signal:
Prices and risks
Price
| Change | Change by industry | Min. | Max. | Volume | |
|---|---|---|---|---|---|
| Yesterday | -1.63% | 2.64% | $765.20 | $772.60 | 621.77M |
| Week | 2.66% | 3.10% | $717.11 | $772.62 | 7.82B |
| Month | -2.50% | 0.45% | $709.00 | $784.34 | 36.90B |
| 3 Months | -12.85% | 0.82% | $677.09 | $908.00 | 97.89B |
| 6 Months | -8.37% | 16.34% | $677.09 | $935.63 | 174.62B |
| Year | -10.94% | 0.64% | $677.09 | $972.53 | 331.88B |
| 3 years | 142.65% | 75.95% | $283.11 | $972.53 | 679.98B |
| 5 years | 407.55% | 100.06% | $129.21 | $972.53 | 884.82B |
| All time | 1,175.11% | 81.24% | $27.21 | $972.53 | 696.96B |
Volatility
| LLY | By industry | |
|---|---|---|
| Yesterday | 15.27% | 1.28% |
| Week | 2.57% | 7.29% |
| Month | 4.21% | 10.86% |
| 3 Months | 17.75% | 20.88% |
| 6 Months | 23.47% | 29.79% |
| Year | 38.51% | 39.37% |
| 3 years | 55.23% | 85.40% |
| 5 years | 72.34% | 115.71% |
| All time | — | — |
- Sortino
- -0.24
- Sharpe
- -0.30
- Sterling
- -0.45
- Liquidity index
- 7.34
- Alpha
- 0.00091
- Beta
- 0.47
AI Factors
Drivers of growth or decline are external factors, selected using AI, that can significantly affect the price of a company's shares in the future.
Fundamental analysis
Indicators for the last quarter and their dynamics for 5 quarters
Ratios
Valuation
Debts
Efficiency
Other ratios
Revenue
Financials
Growth
Assets
Debts
News
About
$729.64B
Capitalization
947.74M
Shares outstanding
Health Care
Sector
Pharmaceuticals
Industry
US5324571083
ISIN
100
Lot size
Mr. David A. Ricks
CEO
Website
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.